Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasia

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 7-11

  Oezdemir, Rena F ^a   Gaisa, Nadine T ^a   Lindemann Docter, Katharina ^a   Gostek, Sonja ^a   Weiskirchen, Ralf ^a   Ahrens, Maike ^b   Schwamborn, Kristina ^c   Stephan, Christian ^b   Pfister, David ^a   Heidenreich, Axel ^a   Knuechel, Ruth ^a   Henkel, Corinna ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Bladder cancer; Classification; Grading; MALDI imaging; Proteomics; Tumor marker

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PAPILLOMA; PRIORITY JOURNAL; PROTEOMICS; TISSUE CHARACTERIZATION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ALGORITHMS; AUTOMATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, STATISTICAL; OBSERVER VARIATION; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84855323298     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.013     Document Type: Article

References (18)

1. MacLennan G.T., Kirkali Z., Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007, 51:889-897. discussion 97-8.
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EROTIC risk tables: a combined analysis of 2596 patients from seven EROTIC trials. Eur Urol 2006, 49:466-5. discussion 75-7.
3. Fernandez-Gomez J., Madero R., Solsona E., Unda M., Martinez-Pineiro L., Gonzalez M., et al. Predicting nonmusical invasive bladder cancer recurrence and progression in patients treated with Bacillus Chalmette-Guerin: the CUERO scoring model. J Urol 2009, 182:2195-2203.
4. Lindemann-Docter K., Knuchel-Clarke R. Histopathology of urothelial carcinomas: crucial for patient management. Urologe A 2008, 47:627-636. quiz 37.
5. Budman L.I., Kassouf W., Steinberg J.R. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008, 2:212-221.
6. Chaux A., Karram S., Miller J.S., Fajardo D.A., Lee T.K., Miyamoto H., et al. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-world health organization/international society of urological pathology classification cohort from a single academic center. Hum Pathol 2011, [Electronic publication ahead of print].
7. Kriegmair M., Baumgartner R., Knuechel R., Steinbach P., Ehsan A., Lumper W., et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994, 44:836-841.
8. Tilki D., Reich O., Svatek R.S., Karakiewicz P.I., Kassouf W., Novara G., et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 2010, 183:1757-1763.
9. Kruskal W.H., Wallis W.A. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952, 583-621.
10. Agresti A., Coull B.A. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 1996, 52:1103-1111.
11. Qiu F., Liu H.Y., Zhang X.J., Tian Y.P. Optimization of magnetic beads for MALDI-TOF MS analysis. Front Biosci 2009, 14:3712-3723.
12. Munro N.P., Cairns D.A., Clarke P., Rogers M., Stanley A.J., Barrett J.H., et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006, 119:2642-2650.
13. Norden A.G., Rodriguez-Cutillas P., Unwin R.J. Clinical urinary peptidomics: learning to walk before we can run. Clin Chem 2007, 53:375-376.
14. Schwamborn K., Krieg R.C., Grosse J., Reulen N., Weiskirchen R., Knuechel R., et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009, 56:989-996.
15. Tolson J.P., Flad T., Gnau V., Dihazi H., Hennenlotter J., Beck A., et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6:697-708.
16. Penno M.A., Ernst M., Hoffmann P. Optimal preparation methods for automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of low molecular weight proteins and peptides. Rapid Commun Mass Spectrom 2009, 23:2656-2662.
17. Schiffer E., Mischak H., Theodorescu D., Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol 2008, 26:67-74.
18. Franck J., Arafah K., Elayed M., Bonnel D., Vergara D., Jacquet A., et al. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics 2009, 8:2023-2033.